Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Management of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development.

Harvey J, Fleetwood A, Ogilvie R, Teasdale A, Wilcox P, Spanhaak S.

Regul Toxicol Pharmacol. 2017 Mar;84:116-123. doi: 10.1016/j.yrtph.2016.12.011. Epub 2016 Dec 27. Review.

PMID:
28038978
2.

Assessing safety of extractables from materials and leachables in pharmaceuticals and biologics - Current challenges and approaches.

Broschard TH, Glowienke S, Bruen US, Nagao LM, Teasdale A, Stults CL, Li KL, Iciek LA, Erexson G, Martin EA, Ball DJ.

Regul Toxicol Pharmacol. 2016 Nov;81:201-211. doi: 10.1016/j.yrtph.2016.08.011. Epub 2016 Aug 26. Review.

PMID:
27569203
3.

Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity.

Ahlberg E, Amberg A, Beilke LD, Bower D, Cross KP, Custer L, Ford KA, Van Gompel J, Harvey J, Honma M, Jolly R, Joossens E, Kemper RA, Kenyon M, Kruhlak N, Kuhnke L, Leavitt P, Naven R, Neilan C, Quigley DP, Shuey D, Spirkl HP, Stavitskaya L, Teasdale A, White A, Wichard J, Zwickl C, Myatt GJ.

Regul Toxicol Pharmacol. 2016 Jun;77:1-12. doi: 10.1016/j.yrtph.2016.02.003. Epub 2016 Feb 13.

PMID:
26879463
4.

Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses.

Amberg A, Beilke L, Bercu J, Bower D, Brigo A, Cross KP, Custer L, Dobo K, Dowdy E, Ford KA, Glowienke S, Van Gompel J, Harvey J, Hasselgren C, Honma M, Jolly R, Kemper R, Kenyon M, Kruhlak N, Leavitt P, Miller S, Muster W, Nicolette J, Plaper A, Powley M, Quigley DP, Reddy MV, Spirkl HP, Stavitskaya L, Teasdale A, Weiner S, Welch DS, White A, Wichard J, Myatt GJ.

Regul Toxicol Pharmacol. 2016 Jun;77:13-24. doi: 10.1016/j.yrtph.2016.02.004. Epub 2016 Feb 11.

5.

Establishing best practise in the application of expert review of mutagenicity under ICH M7.

Barber C, Amberg A, Custer L, Dobo KL, Glowienke S, Van Gompel J, Gutsell S, Harvey J, Honma M, Kenyon MO, Kruhlak N, Muster W, Stavitskaya L, Teasdale A, Vessey J, Wichard J.

Regul Toxicol Pharmacol. 2015 Oct;73(1):367-77. doi: 10.1016/j.yrtph.2015.07.018. Epub 2015 Aug 4.

PMID:
26248005
6.

Controlled Extraction Studies Applied to Polyvinyl Chloride and Polyethylene Materials: Conclusions from the ELSIE Controlled Extraction Pilot Study.

Teasdale A, Jahn M, Bailey S, Feilden A, Taylor G, Corcoran ML, Malick R, Jenke D, Stults CL, Nagao LM.

AAPS PharmSciTech. 2015 Jun;16(3):664-74. doi: 10.1208/s12249-014-0249-x. Epub 2014 Dec 16.

7.

Birth and developmental correlates of birth weight in a sample of children with potential sensory processing disorder.

Gill SV, May-Benson TA, Teasdale A, Munsell EG.

BMC Pediatr. 2013 Feb 25;13:29. doi: 10.1186/1471-2431-13-29.

8.

Boronic acids-a novel class of bacterial mutagen.

O'Donovan MR, Mee CD, Fenner S, Teasdale A, Phillips DH.

Mutat Res. 2011 Sep 18;724(1-2):1-6. doi: 10.1016/j.mrgentox.2011.05.006. Epub 2011 May 26.

PMID:
21645632
9.

Control and analysis of hydrazine, hydrazides and hydrazones--genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products.

Elder DP, Snodin D, Teasdale A.

J Pharm Biomed Anal. 2011 Apr 5;54(5):900-10. doi: 10.1016/j.jpba.2010.11.007. Epub 2010 Nov 13. Review.

PMID:
21145684
10.

The utility of sulfonate salts in drug development.

Elder DP, Delaney E, Teasdale A, Eyley S, Reif VD, Jacq K, Facchine KL, Oestrich RS, Sandra P, David F.

J Pharm Sci. 2010 Jul;99(7):2948-61. doi: 10.1002/jps.22058. Review.

PMID:
20112423
11.

Analytical approaches for the detection of epoxides and hydroperoxides in active pharmaceutical ingredients, drug products and herbals.

Elder DP, Snodin D, Teasdale A.

J Pharm Biomed Anal. 2010 Apr 6;51(5):1015-23. doi: 10.1016/j.jpba.2009.11.023. Epub 2009 Dec 3. Review.

PMID:
20031361
12.

Incidence of pre-, peri-, and post-natal birth and developmental problems of children with sensory processing disorder and children with autism spectrum disorder.

May-Benson TA, Koomar JA, Teasdale A.

Front Integr Neurosci. 2009 Nov 11;3:31. doi: 10.3389/neuro.07.031.2009. eCollection 2009.

13.

Development and validation of an automated static headspace gas chromatography-mass spectrometry (SHS-GC-MS) method for monitoring the formation of ethyl methane sulfonate from ethanol and methane sulfonic acid.

Jacq K, Delaney E, Teasdale A, Eyley S, Taylor-Worth K, Lipczynski A, Reif VD, Elder DP, Facchine KL, Golec S, Oestrich RS, Sandra P, David F.

J Pharm Biomed Anal. 2008 Dec 15;48(5):1339-44. doi: 10.1016/j.jpba.2008.09.028. Epub 2008 Sep 27.

PMID:
18996665
14.

Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs).

Elder DP, Lipczynski AM, Teasdale A.

J Pharm Biomed Anal. 2008 Nov 4;48(3):497-507. doi: 10.1016/j.jpba.2008.06.009. Epub 2008 Jun 25. Review.

PMID:
18657926
15.

Control and analysis of alkyl esters of alkyl and aryl sulfonic acids in novel active pharmaceutical ingredients (APIs).

Elder DP, Teasdale A, Lipczynski AM.

J Pharm Biomed Anal. 2008 Jan 7;46(1):1-8. Epub 2007 Oct 16. Review.

PMID:
18053672
16.

Preferences of therapists-in-training for client characteristics.

Teasdale AC, Hill CE.

Psychotherapy (Chic). 2006 Spring;43(1):111-8. doi: 10.1037/0033-3204.43.1.111.

PMID:
22121963
17.

Late presentation of tracheo-oesophageal fistula.

Teasdale AR, Nielsen MS.

Anaesthesia. 1994 Apr;49(4):307-8. No abstract available.

18.

Ischaemic lesions related to pressure from the bindings of a wrist splint and cardiopulmonary bypass.

Luscombe F, Teasdale A, Powell J.

Anaesthesia. 1989 Jul;44(7):610-1. No abstract available.

19.

Tracheomalacia masquerading as asthma.

McLeod dT, Teasdale AR.

Cent Afr J Med. 1987 Jun;33(6):154-6. No abstract available.

PMID:
3450407

Supplemental Content

Loading ...
Support Center